Biondo Investment Advisors LLC Invests $1.33 Million in PROCEPT BioRobotics Corporation $PRCT

Biondo Investment Advisors LLC purchased a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) in the second quarter, according to its most recent filing with the SEC. The fund purchased 59,120 shares of the company's stock, valued at approximately $1,335,000. Biondo Investment Advisors LLC owned about 0.10% of PROCEPT BioRobotics at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. Versant Capital Management Inc boosted its position in PROCEPT BioRobotics by 994.5% during the 2nd quarter. Versant Capital Management Inc now owns 1,193 shares of the company's stock valued at $27,000 after purchasing an additional 1,084 shares during the period. Caitong International Asset Management Co. Ltd lifted its holdings in PROCEPT BioRobotics by 436.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company's stock worth $29,000 after purchasing an additional 746 shares during the period. Center for Financial Planning Inc. bought a new position in shares of PROCEPT BioRobotics in the fourth quarter valued at approximately $40,000. Cache Advisors LLC bought a new position in PROCEPT BioRobotics during the 1st quarter valued at $42,000. Finally, Essential Partners LLC boosted its stake in PROCEPT BioRobotics by 7,071.4% during the first quarter. Essential Partners LLC now owns 2,008 shares of the company's stock valued at $50,000 after buying an additional 1,980 shares in the last quarter. Institutional investors own 89.46% of the company's stock.

Wall Street Analyst Weigh In

PRCT has been the topic of several recent analyst reports. Piper Sandler cut their price objective on PROCEPT BioRobotics from $35.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, August 5th. TD Cowen reduced their price objective on PROCEPT BioRobotics from $34.00 to $28.00 and set a "buy" rating for the company in a research report on Wednesday, August 5th. William Blair downgraded shares of PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 5th. Leerink Partners lowered shares of PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating and dropped their price target for the company from $31.00 to $29.00 in a research report on Thursday, June 11th. Finally, UBS Group downgraded shares of PROCEPT BioRobotics from a "buy" rating to a "neutral" rating and set a $20.00 price objective on the stock. in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $28.00.

Insider Buying and Selling at PROCEPT BioRobotics

In other news, CEO Larry L. Wood bought 23,900 shares of the business's stock in a transaction on Friday, August 7th. The shares were purchased at an average price of $20.85 per share, for a total transaction of $498,315.00. Following the purchase, the chief executive officer owned 23,900 shares of the company's stock, valued at approximately $498,315. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 1,000 shares of company stock worth $28,480 over the last ninety days. 4.00% of the stock is owned by corporate insiders.

Key PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Multiple law firms reminded investors that September 22, 2026 is the deadline to seek appointment as lead plaintiff in a class action covering purchases of PROCEPT stock from February 28, 2024, through February 25, 2026. These announcements are largely duplicative investor-solicitation notices rather than new company disclosures. Kaplan Fox class-action deadline notice
• Negative Sentiment: The lawsuits allege that PROCEPT failed to disclose inventory problems, including excess customer inventory tied to late-quarter bulk discounts, while investors focused on handpiece sales as a measure of procedure demand. The allegations claim that later revelations led to a substantial stock decline, including an approximately 18% drop referenced in one notice and a decline of more than 75% from the class-period high in another. Hagens Berman PROCEPT class-action notice
• Negative Sentiment: The litigation introduces potential legal costs, reputational risk and further scrutiny of PROCEPT’s sales practices, inventory management and underlying procedure demand. The notices do not establish wrongdoing, and no new operational update or company response was provided in the supplied articles. Kahn Swick and Foti PROCEPT securities-fraud notice

PROCEPT BioRobotics Stock Performance

PRCT stock opened at $21.68 on Monday. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.55 and a quick ratio of 5.35. PROCEPT BioRobotics Corporation has a fifty-two week low of $16.67 and a fifty-two week high of $42.43. The stock has a market capitalization of $1.24 billion, a PE ratio of -11.18 and a beta of 0.89. The company has a 50 day moving average price of $20.40 and a 200 day moving average price of $24.17.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The business had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. During the same period in the previous year, the business posted ($0.35) earnings per share. PROCEPT BioRobotics's revenue was up 19.3% compared to the same quarter last year. Analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source